Immunotherapy is also under research, but the efficacy of PD-1/PDL-1 or CTLA-4 inhibitors in all thyroid cancer subtypes is different and novel strategies in the immune cell cycle are needed to achieve better responses. This evidence concerns the gene CTLA4 and thyroid cancer.